Linda E Kelemen1,2, Peter F Rambau3,4, Jennifer M Koziak5, Helen Steed6, Martin Köbel4. 1. Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Bioengineering Building, MSC955, 68 President Street, Charleston, SC, 29425, USA. kelemen@musc.edu. 2. Hollings Cancer Center, Medical University of South Carolina, 86 Jonathan Lucas Street, Charleston, SC, 29425, USA. kelemen@musc.edu. 3. Department of Pathology, Catholic University of Health and Allied Sciences-Bugando, Mwanza, Tanzania. 4. Calgary Laboratory Services/Alberta Health Services, Department of Pathology and Laboratory Medicine, University of Calgary, 1403 29 Street NW, Calgary, AB, T2N 2T9, Canada. 5. Alberta Health Services-Cancer Control Alberta, 2210 2nd Street SW, Calgary, AB, T2S 3C3, Canada. 6. Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, S5-131 Lois Hole Hospital, Royal Alexandra Hospital, 10240 Kingsway Ave, Edmonton, AB, T5H 3V9, Canada.
Abstract
PURPOSE: Synchronous endometrial and ovarian tumors (SEOs) are diagnosed in 10% of ovarian cancer patients. We examined predictors of SEOs, evaluated associations of SEOs with survival and characterized ovarian tumor profiles using immunohistochemistry. METHODS: We included patients with endometrioid (n = 180) and clear cell (n = 165) ovarian carcinoma identified from the Alberta Cancer Registry between 1979 and 2010 for whom we abstracted medical records and constructed tumor tissue microarrays (TMAs). A concurrent diagnosis of endometrial cancer was obtained from the medical chart. We used unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) and Cox proportional hazards models to estimate hazard ratios (HRs) and 95% CIs. Protein expression in ovarian tumors of patients with and without SEOs was evaluated using Fisher's exact test. RESULTS: Comparing 52 patients with SEO tumors to 293 patients with endometrioid or clear cell ovarian carcinomas, endometriosis at the ovary (OR = 0.45, 95% CI = 0.23-0.87, p = 0.02) was the strongest predictor of decreased risk in multivariable models. Premenopausal status (OR = 2.17, 95% CI = 0.92-5.13, p = 0.08) and lower pre-treatment CA125 levels (OR = 0.17, 95% CI = 0.02-1.32, p = 0.09) showed weaker associations. There were no significant differences in survival between patients with or without SEO tumors. More patients with SEO tumors compared to endometrioid ovarian carcinoma were deficient in MLH1, PMS2 and PTEN (p ≤ 0.03). CONCLUSIONS: Endometriosis may not be the mechanism by which SEO cancers arise. Altered tumor oncoprotein expression between women with and without SEOs indicates important biological differences although this did not translate into prognostic differences.
PURPOSE: Synchronous endometrial and ovarian tumors (SEOs) are diagnosed in 10% of ovarian cancerpatients. We examined predictors of SEOs, evaluated associations of SEOs with survival and characterized ovarian tumor profiles using immunohistochemistry. METHODS: We included patients with endometrioid (n = 180) and clear cell (n = 165) ovarian carcinoma identified from the Alberta Cancer Registry between 1979 and 2010 for whom we abstracted medical records and constructed tumor tissue microarrays (TMAs). A concurrent diagnosis of endometrial cancer was obtained from the medical chart. We used unconditional logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) and Cox proportional hazards models to estimate hazard ratios (HRs) and 95% CIs. Protein expression in ovarian tumors of patients with and without SEOs was evaluated using Fisher's exact test. RESULTS: Comparing 52 patients with SEO tumors to 293 patients with endometrioid or clear cell ovarian carcinomas, endometriosis at the ovary (OR = 0.45, 95% CI = 0.23-0.87, p = 0.02) was the strongest predictor of decreased risk in multivariable models. Premenopausal status (OR = 2.17, 95% CI = 0.92-5.13, p = 0.08) and lower pre-treatment CA125 levels (OR = 0.17, 95% CI = 0.02-1.32, p = 0.09) showed weaker associations. There were no significant differences in survival between patients with or without SEO tumors. More patients with SEO tumors compared to endometrioid ovarian carcinoma were deficient in MLH1, PMS2 and PTEN (p ≤ 0.03). CONCLUSIONS: Endometriosis may not be the mechanism by which SEO cancers arise. Altered tumor oncoprotein expression between women with and without SEOs indicates important biological differences although this did not translate into prognostic differences.
Authors: Lea A Moukarzel; Arnaud Da Cruz Paula; Lorenzo Ferrando; Timothy Hoang; Ana Paula Martins Sebastiao; Fresia Pareja; Kay J Park; Achim A Jungbluth; Gabriel Capella; Marta Pineda; Jeffrey D Levin; Nadeem R Abu-Rustum; Lora H Ellenson; August Vidal Bel; Jorge S Reis-Filho; Xavier Matias-Guiu; Karen Cadoo; Zsofia K Stadler; Britta Weigelt Journal: Mod Pathol Date: 2020-12-16 Impact factor: 7.842
Authors: Amit Atwal; Tristan Snowsill; Marcus Cabrera Dandy; Thomas Krum; Claire Newton; Dafydd Gareth Evans; Emma J Crosbie; Neil A J Ryan Journal: Int J Cancer Date: 2022-07-06 Impact factor: 7.316
Authors: Courtney D Bailey; Rebecca Previs; Bryan M Fellman; Tarrik Zaid; Marilyn Huang; Alaina Brown; Ahmed Enbaya; Nyla Balakrishnan; Russell R Broaddus; Diane C Bodurka; Pamela Soliman; Nicole D Fleming; Alpa Nick; Anil K Sood; Shannon Neville Westin Journal: Int J Gynecol Cancer Date: 2020-10-29 Impact factor: 3.437
Authors: Anna Myriam Perrone; Giulia Girolimetti; Martina Procaccini; Lorena Marchio; Alessandra Livi; Giulia Borghese; Anna Maria Porcelli; Pierandrea De Iaco; Giuseppe Gasparre Journal: Int J Mol Sci Date: 2018-07-13 Impact factor: 5.923